Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
November 08, 2021 08:00 ET | Phathom Pharmaceuticals
Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May...
July 30, 2021 - ROSEN LOGO.jpg
ARDX FINAL DEADLINE TUESDAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action – ARDX
September 26, 2021 15:15 ET | The Rosen Law Firm PA
NEW YORK, Sept. 26, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
Orphalan.png
Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease
September 02, 2021 02:00 ET | Orphalan
Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA supported by positive data from...
July 30, 2021 - ROSEN LOGO.jpg
ARDX INVESTOR NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
August 19, 2021 16:15 ET | The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
July 30, 2021 - ROSEN LOGO.jpg
ITRM NOTICE: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED LAW FIRM, Encourages Iterum Therapeutics plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ITRM
August 19, 2021 14:15 ET | The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
July 30, 2021 - ROSEN LOGO.jpg
ARDX INVESTOR NEWS: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
August 13, 2021 18:15 ET | The Rosen Law Firm PA
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LONGSTANDING LAW FIRM, Encourages Iterum Therapeutics plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – ITRM
August 11, 2021 19:45 ET | The Rosen Law Firm PA
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Iterum...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A RESPECTED AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – ARDX
August 03, 2021 15:45 ET | The Rosen Law Firm PA
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Firm_Logo_November_2020 (2).jpg
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages CorMedix Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – CRMD
July 28, 2021 09:49 ET | The Rosen Law Firm PA
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
logo color s and clearside.jpg
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
May 03, 2021 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...